Stock AYTU AYTU BIOSCIENCE INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Aytu Bioscience Inc OTC Bulletin Board

Equities

AYTU

US0547542052

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for Aytu Bioscience Inc
15/05 Transcript : Aytu BioPharma, Inc., Q3 2024 Earnings Call, May 15, 2024
15/05 Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q3 Revenue $18M, vs. Street Est of $17.4M MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Transcript : Aytu BioPharma, Inc., Q3 2024 Earnings Call, May 15, 2024
Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q3 Revenue $18M, vs. Street Est of $17.4M
MT
Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024
Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M
MT
Aytu BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
CI
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
AQ
Transcript : Aytu BioPharma, Inc., Q1 2024 Earnings Call, Nov 14, 2023
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q1 Revenue $22.1M, vs. Street Est of $27.7M
MT
Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023
CI
Aytu BioPharma Gets FDA Approval to Transfer Production of Cotempla to Third Party
MT
Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement
CI
Aytu BioPharma, Inc. Announces Resignation of Christopher Brooke as Chief Operating Officer
CI
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q4 Revenue $30.7M, vs. Street Est of $27.7M
MT
Aytu BioPharma, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2023
CI
Aytu BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023
CI
North American Morning Briefing : Stock Futures Helped by Retreating Bond Yields
DJ
Aytu BioPharma to Present at LD Micro Main Event XVI Conference
AQ
Maxim Starts Aytu BioPharma at Buy With $5 Price Target
MT
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT and Cotempla XR-ODT in Israel and the Palestinian Authority
AQ
Aytu BioPharma, Inc. Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-OT(R) in Israel and the Arab Authority
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AYTU Stock
  4. AYTU Stock
  5. News Aytu Bioscience Inc